Payment overview · 2025
General Payments
$7,515.59
32 reported records · 16 companies
Healthcare provider profile · identity verified
Nitin Trivedi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · WORCESTER, MA · NPI 1770543977
Verified facts
What the public records show
CMS Open Payments records show Nitin Trivedi, M.D. received $7,515.59 in general payments during 2025 across 32 reported records.
Dexcom, Inc. accounted for 89.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Synthroid, Tirosint.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tirosint as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tirosint by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 474 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $6,732.64 | 89.6% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $264.50 | 3.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $131.55 | 1.8% | 5 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $69.85 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.46 | 0.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.86 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.81 | 0.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.01 | 0.4% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.67 | 0.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $26.46 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.73 | 0.3% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $23.08 | 0.3% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $21.11 | 0.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.18 | 0.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.85 | 0.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.83 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $6,511.00 | 3 |
| Food and Beverage | $975.33 | 27 |
| Travel and Lodging | $29.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $6,732.64 | 8 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $6,732.64 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $96.05 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $87.16 | 3 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $69.85 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.80 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 474 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 103 | exact normalized | Medicare Part D |
| Tirosint tirosint |
2025 | Tirosint | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 25 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Tirosint open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Tirosint · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
474 | 104 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 474 | 104 |
| Trulicity | Dulaglutide | 446 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 101 |
| Jardiance | Empagliflozin | 328 | 64 |
| Mounjaro | Tirzepatide | 288 | 60 |
| Tresiba Flextouch U-100 | Insulin Degludec | 187 | 52 |
| Metformin Hcl | Metformin Hcl | 181 | 56 |
| Metformin Hcl Er | Metformin Hcl | 171 | 50 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 150 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 43 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 125 | 39 |
| Alendronate Sodium | Alendronate Sodium | 115 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 114 | 31 |
| Synthroid | Levothyroxine Sodium | 103 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 100 | 22 |
| Farxiga | Dapagliflozin Propanediol | 99 | 17 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 92 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 80 | 17 |
| Novolog Flexpen | Insulin Aspart | 79 | 24 |
| Humalog | Insulin Lispro | 78 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 75 | 16 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 74 | 22 |
| Januvia | Sitagliptin Phosphate | 69 | 16 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 68 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 19 |
| Glipizide Er | Glipizide | 55 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 54 | 20 |
| Novolog | Insulin Aspart | 52 | 13 |
| Gabapentin | Gabapentin | 51 | 13 |
| Vascepa | Icosapent Ethyl | 49 | suppressed |
| Glimepiride | Glimepiride | 47 | 12 |
| Losartan Potassium | Losartan Potassium | 44 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 41 | suppressed |
| Hydrocortisone | Hydrocortisone | 40 | suppressed |
| Methimazole | Methimazole | 37 | suppressed |
| Prolia | Denosumab | 37 | 25 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 34 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 15 |
| Rybelsus | Semaglutide | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lisinopril | Lisinopril | 30 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Testosterone | Testosterone | 28 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 27 | suppressed |
| Tymlos | Abaloparatide | 26 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 20 |
| Tirosint | Levothyroxine Sodium | 22 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | 11 |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Humalog Junior Kwikpen | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,515.59 · 32 records | Dexcom, Inc. | CRYSVITA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, EVENITY, FREESTYLE LIBRE 3, Flector, ISTURISA, Kerendia, Korlym, LEQVIO, Licart, MINIMED 780G, Ozempic, REZDIFFRA, Rybelsus, SYNTHROID, TWIIST, Tirosint, Veozah, Yorvipath | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error